DISPOSITION OF CLOZAPINE AND DESMETHYLCLOZAPINE IN SCHIZOPHRENIC-PATIENTS

被引：34
|
作者：
LIN, SK
CHANG, WH
CHUNG, MC
LAM, YWF
JANN, MW
机构：
[1] TAIPEI CITY PSYCHIAT CTR,BIOL PSYCHIAT LAB,TAIPEI 10510,TAIWAN
[2] UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,DIV CLIN PHARM,SAN ANTONIO,TX 78284
[3] UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712
[4] MERCER UNIV,DEPT PHARM PRACTICE,ATLANTA,GA
[5] MERCER UNIV,DEPT PHARMACEUT SCI,ATLANTA,GA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 34卷 / 04期
关键词：
D O I：
10.1002/j.1552-4604.1994.tb02000.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The disposition of the atypical clozapine and its desmethyl metabolite were evaluated in fourteen male chronic patients. A single 100 mg dose of clozapine was administered and blood sampling performed over the following 72 hours. The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively. The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively. The elimination of the metabolite is rate limited by its formation from cloza-pine. A wide interpatient variability in clozapine and desmethylclozapine pharmacokinetics was observed.
引用
收藏
页码：318 / 324
页数：7
相关论文
共 50 条
  • [21] CAUDATE NUCLEI VOLUMES IN SCHIZOPHRENIC-PATIENTS TREATED WITH TYPICAL ANTIPSYCHOTICS OR CLOZAPINE
    CHAKOS, MH
    LIEBERMAN, JA
    ALVIR, J
    BILDER, R
    ASHTARI, M
    LANCET, 1995, 345 (8947): : 456 - 457
  • [22] PLASMA-LEVELS AND DOSING STRATEGIES IN SCHIZOPHRENIC-PATIENTS RECEIVING CLOZAPINE
    BUCKLEY, PF
    COLA, PA
    HASEGAWA, N
    LYS, C
    MELTZER, HY
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 144 - 145
  • [23] HORMONAL RESPONSE TO FENFLURAMINE CHALLENGES IN CLOZAPINE-TREATED SCHIZOPHRENIC-PATIENTS
    LEMUS, CZ
    LIEBERMAN, JA
    JOHNS, CA
    MAYERHOFF, DI
    POLLACK, S
    COOPER, TB
    NOVACENKO, H
    BIOLOGICAL PSYCHIATRY, 1991, 29 (07) : 691 - 694
  • [24] Neuroleptic-resistant schizophrenic patients treated by clozapine: Clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels
    Aymard, N
    Baldacci, C
    Leyris, A
    Smagghe, PO
    Tribolet, S
    Vacheron, MN
    Viala, A
    Caroli, F
    THERAPIE, 1997, 52 (03): : 227 - 232
  • [25] THE SAFETY AND EFFICACY OF CLOZAPINE IN SEVERE TREATMENT-RESISTANT SCHIZOPHRENIC-PATIENTS IN THE UK
    ADAMS, CE
    BARNES, TRE
    ESSALI, MA
    HIRSCH, SR
    MACKAY, AVP
    CORRIGAN, FM
    CUTTING, JC
    EKDAWI, MY
    MCKENNA, PJ
    MILLN, PTS
    PARKER, AL
    LADER, M
    BROWNSEY, RL
    BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 : 150 - 154
  • [26] BLOOD POLYAMINES IN SCHIZOPHRENIA - A STUDY OF CLOZAPINE IN DRUG-RESISTANT SCHIZOPHRENIC-PATIENTS
    DAS, I
    ADAMS, C
    ESSALI, MA
    DEBELLEROCHE, J
    HIRSCH, SR
    SCHIZOPHRENIA RESEARCH, 1992, 6 (02) : 175 - 175
  • [27] CLOZAPINE IN THE TREATMENT OF FIRST-EPISODE AND MULTI-EPISODE SCHIZOPHRENIC-PATIENTS
    HUMMER, M
    KURZ, M
    KEMMLER, J
    KURZTHALER, I
    OBERBAUER, H
    FLEISCHHACKER, WW
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 153 - 153
  • [28] CLOZAPINE REDUCES COMPULSIVE WATER DRINKING BEHAVIOR IN SCHIZOPHRENIC-PATIENTS WITH PSYCHOGENIC POLYDIPSIA
    FULLER, M
    VOKAS, C
    STEELE, V
    WHITE, J
    JURJUS, G
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 150 - 150
  • [29] COMPLIANCE IN SCHIZOPHRENIC-PATIENTS
    NOBLE, P
    SCHIZOPHRENIA RESEARCH, 1992, 6 (02) : 108 - 108
  • [30] MOTIVATION IN SCHIZOPHRENIC-PATIENTS
    HAAS, WA
    PSYCHOLOGICAL REPORTS, 1963, 12 (03) : 799 - 802
12345